Adverse Drug Event Clinical Trial
Official title:
Partnering With Patients for Improving Medication Safety During Transitions of Care: Implications for Work System Design
This project is to develop, implement, pilot evaluate, and disseminate a medication safety program (HomeTeam) that consolidates strategies to help patients by partnering with patients and their informal caregivers during transitions from hospital to home. Care transitions, especially from hospital to home, are high-risk periods for medication errors, and are frequently associated with serious adverse drug events (ADEs) and preventable readmissions. Older adults with multi-morbid conditions who have complex medication regimes are especially prone to these risks. Patients and family caregivers may experience a dramatic transition in roles and responsibilities immediately after hospital discharge. Patients and family caregivers are relatively passive recipients in their care and medication management in the hospital, but when patients arrive at home, patients have the primary responsibility for their care and medication use (with professional care providers switching to a 'supporting' function). Although this significant transition in the nature and intensity of patient work needs to be managed actively, often patients and family members are not adequately engaged and prepared in the hospital, and not effectively supported for safe medication use after hospital discharge. More specifically, patients and family members may not understand essential steps in the management of their condition, and have difficulty contacting appropriate health care practitioners for guidance. Although most organizations deploy multiple layers of interventions for improving care transitions, reducing postdischarge adverse drug events (ADEs), 30-day readmissions and emergency department (ED) visits, their impact to date has been small, and there remains significant and urgent need to fundamentally redesign the hospital-to-home care transition process. Investigators believe that one practical and potentially effective way for this 'much-needed' redesign is through engaging and supporting patients and families in safe medication use. Investigators' proposed program 'HomeTeam' will contain evidence-based tools and methods for engaging patients and shifting culture towards a truly patient-centered care for medication safety.
The 'HomeTeam will be developed and evaluated by completing 3 specific aims:
Aim #1: Develop components of a multi-faceted program (HomeTeam) that consolidates
evidence-based practices in patient and family activation and engagement related to
medication safety, with the goal to adequately and reliably support transitions from the
hospital to the patient home "work system" for medication management. Inpatient stays and the
hospital discharge periods will be targeted as opportunities in activating, engaging, and
enabling patients and family members to improve medication safety.
(1a) Identify evidence-based practices in patient and family activation and engagement
related to medication safety during care transitions.
1. b) Develop program components (e.g., action-oriented patient/ family education, improved
medication reconciliation, patient-centered rounds, learning systems through systematic
feedback from home care professionals)-including tools to assess, prioritize,
streamline, and integrate existing practices- aimed at engaging patients and families
and supporting medication use safety during care transitions from hospital to home with
a participatory design (PD) approach.
Aim #2: Refine and implement the HomeTeam program in two organizations (one academic,
one community hospital), with a peer-to-peer assessment methodology to identify and
refine patient and family engagement practices for transitional care medication safety.
2. a) Refine HomeTeam program through participatory design approach and peer-to-peer
assessment
(2b) Implement and pilot test HomeTeam in all participating sites
Aim #3: Evaluate the implementation process and the impact of the toolkit 'HomeTeam' on
medication safety after hospital discharge. Investigators will use a pre-post design to
evaluate the impact of the toolkit over a one year period, focusing on 65 years of age and
older medicine patients. The primary outcome is preventable and ameliorable adverse drug
events (ADEs) after discharge. Secondary outcomes include 30-day post-discharge readmissions
and ED visits due to medication-related issues process improvement assessment,
patient-reported outcomes, and toolkit adoption assessment (e.g., acceptability,
feasibility). Qualitative methods (post-implementation interviews with clinicians and
patient/ family members) will be used as part of the evaluation.
Hypothesis: Investigators hypothesize that the HomeTeam Medication Safety Program will reduce
preventable and ameliorable post-discharge 30-day ADEs in the following subpopulations: older
adults with at least 5 medications discharged from hospital to home on (H01) anticoagulants,
(H0b) opioids, (H0c) diabetes agents.
The project will be conducted in two hospitals: Bayview Medical Center (academic) and Howard
County Medical Center (community). Dissemination plans include national medication safety
organizations (e.g., Institute for Safe Medication Practices), patient safety organizations
(e.g., Batz Patient Safety Foundation), and professional societies (e.g., Society of Hospital
Medicine). Different dissemination modalities are planned, including story-telling through
social media and short videos targeted for patients and clinicians.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03638726 -
Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
|
Phase 4 | |
Completed |
NCT05007041 -
Simultaneous RZV and aIIV4 Vaccination
|
Phase 4 | |
Suspended |
NCT02559960 -
Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
|
||
Completed |
NCT05266300 -
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
|
||
Completed |
NCT03112083 -
Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure
|
N/A | |
Completed |
NCT05028361 -
Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
|
Phase 4 | |
Completed |
NCT04284553 -
Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults
|
N/A | |
Recruiting |
NCT06120712 -
A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002)
|
Phase 1/Phase 2 | |
Completed |
NCT04181775 -
Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)
|
||
Completed |
NCT02906657 -
Medication Reconciliation Using Electronic Pharmaceutical Record: A Multicenter Study in the Hospitalized Elderly
|
N/A | |
Completed |
NCT03640273 -
Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients
|
Phase 2 | |
Completed |
NCT02162147 -
How Safe Are Our Pediatric Emergency Departments?
|
N/A | |
Completed |
NCT01897870 -
The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge.
|
N/A | |
Completed |
NCT03725046 -
Impact of an Optimized Communication on the Readmission for Adverse Drug Event
|
N/A | |
Recruiting |
NCT04635956 -
Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas
|
Phase 2 | |
Active, not recruiting |
NCT05538065 -
NUDGE-EHR Replication Trial at Mass General Brigham
|
N/A | |
Completed |
NCT03442010 -
Adverse Drug Events at Emergency Department
|
||
Recruiting |
NCT04791150 -
Rheumatologic Adverse Events and Cancer Immunotherapy
|
N/A | |
Completed |
NCT02864030 -
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
|
Phase 4 | |
Completed |
NCT03665402 -
A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status
|
N/A |